This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

HIV disease resulting in mycobacterial infection마이코박테리아감염을 유발한 HIV 감염병 (HIV 마이코박테리아 감염증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: B20.0 (HIV disease resulting in mycobacterial infection) | Special Copayment Reduction: V103 (serious illness related to HIV infection, 10% copayment for 5 years after registration)
B. SynonymsHIV disease resulting in tuberculosis, HIV-TB co-infection, HIV mycobacterial infection, HIV-associated tuberculosis, HIV-MAC disease
C. Adult onsetLikelihood of first onset in adulthood: very high — HIV infection itself is mainly diagnosed in adulthood, and mycobacterial infection (tuberculosis and MAC) occurs in adulthood (mostly 30s–60s) when immunosuppression has progressed.
1. HistoryFirst description of AIDS in 1981 → discovery of HIV in 1984 → surge of MAC opportunistic infections in the mid-1980s → decrease of opportunistic infections after the introduction of ART in 1996 → HIV-TB co-infection emerges as a global problem in the 2010s → WHO 2023 integrated HIV-TB guidelines.
2. CausesMain pathogens: Mycobacterium tuberculosis (tuberculosis; possible at any CD4 level, especially <200), Mycobacterium avium complex (MAC; occurs mainly at CD4 <50/μL), and nontuberculous mycobacteria (NTM) such as M. kansasii. CD4 T-cell depletion by HIV is central to tuberculosis reactivation and MAC dissemination.
3. GeneticsHost immune genes such as HLA-B57:01, CCR5-Δ32, and HLA-B*35 influence susceptibility to HIV and tuberculosis. Analysis of genes associated with drug resistance of M. tuberculosis (MDR, XDR) (katG, rpoB, inhA) is clinically important.
4. General epidemiologyAbout 1 million people worldwide with HIV/TB co-infection (2022, WHO). Incidence of MAC in HIV patients before ART about 25–43%/year (CD4 <50). Dropped sharply after ART. The incidence of tuberculosis in HIV patients in Korea is 10–20 times that of the general population. About 1,250 new HIV notifications in Korea in 2022.
5. PathophysiologyHIV → CD4 T-cell depletion → weakened Th1 response → reduced mycobacterial killing capacity within macrophages → reactivation of latent tuberculosis infection or progression of primary infection, disseminated MAC infection. Upon ART initiation, tuberculosis/MAC lesions may transiently worsen due to immune reconstitution inflammatory syndrome (IRIS).
6. SymptomsHIV-TB: fever, night sweats, weight loss, cough (in pulmonary tuberculosis), lymphadenopathy. HIV-MAC: fever (38.5°C or above), night sweats, extreme weight loss, abdominal pain, diarrhea, anemia. Extrapulmonary or disseminated tuberculosis (lymph node, abdominal, meningeal) is common in HIV.
7. SignsLymphadenopathy (generalized), hepatosplenomegaly. HIV-MAC: positive blood culture for MAC, anemia (Hb <10), elevated alkaline phosphatase. HIV-TB: chest X-ray (upper-lobe infiltrates, miliary pattern), sputum AFB smear, IGRA/TST (frequent false negatives). GeneXpert MTB/RIF is key for rapid diagnosis.
8. ScreeningLatent tuberculosis infection testing (IGRA or TST) in all HIV patients. Symptom assessment before MAC prophylaxis at CD4 <50/μL. Korean HIV treatment guidelines: tuberculosis screening at least once a year. Enhanced tuberculosis screening for those with a history of residence in high-risk regions (Africa, Southeast Asia).
9. DiagnosisHIV-TB: GeneXpert MTB/RIF (rapid; sputum/tissue), sputum AFB culture and identification, drug resistance testing (molecular and phenotypic). HIV-MAC: blood mycobacterial culture (MAC-specific medium), bone marrow/lymph node biopsy. Latent tuberculosis: IGRA (QuantiFERON-TB Gold Plus, etc.).
10. TreatmentHIV-TB: standard 6-month antituberculosis regimen (2HRZE/4HR) + ART (start within 2–8 weeks; immediately if CD4 <50). HIV-MAC: clarithromycin + ethambutol ± rifabutin combination, ART started concurrently. Latent tuberculosis: INH for 9 months or INH + rifampin for 3 months. Consider steroids for IRIS.
11. PrognosisWith ART + antituberculosis combination therapy, the treatment success rate for HIV-TB is over 80%. In HIV-MAC, symptoms improve and survival is better with ART combined with anti-MAC treatment. Poor prognosis with MDR-TB/XDR-TB co-infection. Life expectancy of ART-adherent patients in Korea is nearly normalized.
12. PreventionTreatment of latent tuberculosis (INH preventive chemotherapy). MAC prophylaxis with azithromycin or clarithromycin at CD4 <50/μL (stop when CD4 recovers after ART initiation). BCG vaccination. Preserve immunity by starting ART early.
13. ReferencesWHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. 2021 … and 9 other papers

1. History

The association between HIV infection and mycobacterial infection was recognized from the early days of the AIDS epidemic. Shortly after the US CDC reported unusual Pneumocystis pneumonia and Kaposi's sarcoma in gay men in 1981, it was noted that tuberculosis and nontuberculous mycobacterial (NTM) infections were surging in patients with this new immunodeficiency syndrome. After HIV was identified as the causative virus of AIDS in 1984, the pathophysiologic link was established that CD4 T-cell depletion by HIV greatly weakens host defense against mycobacteria.

In the era before the introduction of highly active ART, from the mid-1980s to the early 1990s, Mycobacterium avium complex (MAC) was one of the most common AIDS-related bacterial opportunistic infections. In AIDS patients whose CD4 count fell to 50/μL or below, disseminated MAC disease occurred at a frequency of 25–43% per year, causing fever, weight loss, anemia, and death. Tuberculosis, combined with HIV infection especially in tuberculosis-endemic regions such as Africa, Asia, and Latin America, became a leading cause of death in AIDS.

The introduction of highly active ART (HAART) in 1996 dramatically reduced the occurrence of opportunistic infections, including MAC and tuberculosis. However, in low- and middle-income countries where the global prevalence of tuberculosis remains high, HIV-TB co-infection continues to cause high mortality. The WHO reported that in 2022 there were about 1.07 million HIV-positive tuberculosis patients worldwide, with markedly higher mortality than HIV-negative tuberculosis patients. Since the 2010s, co-infection of drug-resistant tuberculosis (MDR-TB, XDR-TB) and HIV has emerged as a core challenge in international public health.

In Korea, tuberculosis and MAC infection in HIV patients have decreased since the 2000s, when ART became widely available, but the incidence of tuberculosis in HIV patients is still 10–20 times higher than in the general population, so tuberculosis screening and treatment of latent tuberculosis are strongly recommended in HIV treatment guidelines.


2. Causes

B20.0 covers HIV disease accompanied by mycobacterial infection, and the main pathogens are as follows.

Mycobacterium tuberculosis (tubercle bacillus): the most important cause of mycobacterial infection in HIV-infected patients. Tuberculosis can occur at any CD4 count, but the risk is highest at CD4 <200/μL. HIV infection raises the risk of reactivation of latent tuberculosis infection to 5–10% per year (5–10% over a lifetime in immunocompetent individuals), and the risk of progression after primary infection is also greatly increased. In HIV-TB co-infection, extrapulmonary tuberculosis (lymph node, meninges, abdomen, bone) is very common and shows atypical clinical features.

Mycobacterium avium complex (MAC): a complex of M. avium and M. intracellulare, widely distributed in the environment (soil, water, poultry). It does not cause infection in immunocompetent individuals, but in the severely immunosuppressed state with CD4 <50/μL, disseminated infection occurs by the oral or inhalation route. MAC was the most common bacterial opportunistic infection in AIDS patients in the pre-ART era.

Other nontuberculous mycobacteria (NTM): M. kansasii (lung involvement, CD4 <100/μL), M. haemophilum (skin, joints, bone), M. genavense (disseminated), etc., are reported in HIV-infected patients.

The central mechanism of the increased risk of mycobacterial infection is CD4 T-cell depletion by HIV. Cell-mediated immunity against mycobacteria (Th1 response, IFN-γ production, macrophage activation) is weakened by the decrease in CD4 T cells, so mycobacteria that would have been suppressed in immunocompetent individuals proliferate and disseminate.


3. Genetics

Several host genetic factors are involved in susceptibility to HIV infection and mycobacterial infection. The main gene related to susceptibility to and progression of HIV itself is the CCR5-Δ32 deletion variant of the CCR5 (co-receptor) gene, and homozygotes for this variant show strong resistance to HIV infection. HLA genes (especially HLA-B*57:01, HLA-B*5701) are associated with suppression of HIV progression, whereas HLA-B*35 is associated with rapid AIDS progression.

Host genes related to susceptibility to tuberculosis that have been studied include the SLC11A1 (NRAMP1) gene (involved in killing of mycobacteria within macrophages), the vitamin D receptor (VDR) gene, IL-12/IL-12R pathway genes, and the IFN-γ receptor gene. Among these, there are reports that SLC11A1 polymorphisms are associated with tuberculosis susceptibility in African populations.

Specific genetic studies on susceptibility to MAC infection are limited, but it is known that genetic defects of the interleukin-12/23 pathway and the IFN-γ pathway raise the risk of disseminated nontuberculous mycobacterial infection.

The clinically most important genetic aspect is the drug resistance genes of M. tuberculosis. Molecular detection of the katG S315T mutation associated with isoniazid resistance, rpoB mutations (rifampin resistance), inhA mutations, gyrA mutations (fluoroquinolone resistance), and rrs and eis mutations (aminoglycoside resistance) is essential for early diagnosis of MDR-TB/XDR-TB and selection of tailored treatment. Drug resistance testing based on GeneXpert MTB/RIF and next-generation sequencing is becoming standardized.


4. General epidemiology

According to the WHO Global Tuberculosis Report 2023, about 1.07 million tuberculosis patients worldwide (2022) are HIV-positive, accounting for about 8% of all tuberculosis patients. The mortality of HIV-positive tuberculosis patients is 2–3 times higher than that of HIV-negative tuberculosis patients. About 25–40% of new tuberculosis patients in sub-Saharan Africa are HIV-positive, and HIV-TB co-infection is one of the most important infection-related causes of death in this region.

Looking at HIV epidemiology in Korea, as of 2022 there were about 1,250 newly notified HIV cases and about 18,000 cumulative HIV-infected individuals. More than 70% of HIV/AIDS patients are male, and the main route of infection is sexual contact. The incidence of tuberculosis in HIV patients in Korea is 10–20 times that of the general population (about 40–50 per 100,000 population per year), so tuberculosis screening and treatment of latent tuberculosis are of high clinical importance in HIV patients.

After the introduction of ART, the incidence of disseminated MAC infection has decreased greatly in developed countries, including Korea. In the pre-ART era, the incidence of MAC in AIDS patients with CD4 <50/μL was 25–43% per year, but it fell below 1% after ART. However, MAC infection still occurs in patients who are not on ART or who have an extremely low CD4 count owing to poor adherence.

Co-infection of drug-resistant tuberculosis (MDR-TB, XDR-TB) and HIV is a growing problem worldwide. Of about 410,000 MDR/RR-TB patients worldwide in 2022, about 5–10% were HIV-positive, and treatment success rates in these patients are much lower. In Korea as well, MDR-TB and HIV co-infection is reported sporadically and draws attention as a case requiring multi-institution collaborative treatment.


5. Pathophysiology

The interaction between HIV and mycobacterial infection is immunologically complex, and the two infections form a vicious cycle accelerating each other's progression.

CD4 T-cell depletion and impaired mycobacterial immunity: normal immune defense against mycobacteria depends on a process in which CD4+ T cells produce IFN-γ to activate macrophages, and the activated macrophages kill intracellular mycobacteria through oxidative burst, reactive nitrogen species (NO), and autophagy. CD4 T-cell depletion by HIV fundamentally weakens this defense circuit, allowing tubercle bacilli to proliferate unchecked within macrophages and MAC to cause disseminated infection from the gut and lungs.

HIV-TB interaction: tuberculosis infection itself promotes HIV replication. Components of M. tuberculosis (e.g., lipoarabinomannan) activate the TNF-α, IL-6, and NF-κB pathways in macrophages and T cells, increasing HIV-LTR (long terminal repeat) transcription. This forms a vicious cycle in which tuberculosis and HIV progress simultaneously. In addition, HIV-induced immunosuppression promotes extrapulmonary dissemination of M. tuberculosis, causing atypical clinical features.

Immune reconstitution inflammatory syndrome (IRIS): when the CD4 T-cell count recovers rapidly after ART initiation, an excessive immune response against previously latent tuberculosis or MAC may occur, causing transient worsening of lesions (IRIS). There are two forms, unmasking IRIS (exposure of a previously undiagnosed infection) and paradoxical IRIS (worsening of an infection under treatment), and it occurs within weeks to months after ART initiation. The lower the CD4 and the more infections present before ART initiation, the higher the risk of IRIS.


6. Symptoms

HIV-associated pulmonary and extrapulmonary tuberculosis: the classic tuberculosis symptoms of fever, night sweats, weight loss, and cough lasting 3 weeks or more occur. The lower the CD4 count, the higher the proportion of extrapulmonary tuberculosis (lymph node tuberculosis, tuberculous meningitis, abdominal tuberculosis, spinal tuberculosis, etc.) and the more atypical the clinical features. Miliary tuberculosis occurs far more commonly in HIV patients than in immunocompetent individuals, presenting with fever, malaise, dyspnea, and hepatosplenomegaly. Tuberculous meningitis shows fever, headache, nuchal rigidity, and altered consciousness.

Disseminated MAC infection: chronic fever (38.5°C or above, lasting several weeks or more), night sweats, and extreme weight loss are the most common symptoms. Abdominal pain, diarrhea, and nausea may accompany, and hepatosplenomegaly and generalized lymphadenopathy are observed on physical examination. Chronic anemia is prominent, with marked fatigue as a result. A marked elevation of serum alkaline phosphatase (ALP) is characteristic.

In both infections, nonspecific systemic symptoms may be the main initial symptoms, so differentiation from other opportunistic infections (CMV infection, lymphoma, etc.) is important. If fever persists for 2 weeks or more in an HIV patient, systematic differential diagnostic tests including tuberculosis, MAC, CMV infection, and lymphoma are needed.


7. Signs

HIV-TB-related signs: chest X-ray may show upper-lobe infiltrates, miliary nodules (miliary pattern), cavity formation, and pleural effusion. At CD4 <200/μL, lower-lobe infiltrates, diffuse ground-glass opacity, and miliary patterns are more common than the typical upper-lobe cavitary lesions. Necrotic lymphadenopathy on CT is an important finding of extrapulmonary tuberculosis. Sputum acid-fast bacilli (AFB) smear has a high false-negative rate in HIV patients. GeneXpert MTB/RIF is the key test for diagnosing tuberculosis in HIV patients (applicable to various specimens such as sputum, lymph node, and CSF). IGRA (interferon-gamma release assay) frequently gives false negatives at CD4 <200/μL.

HIV-MAC-related signs: blood mycobacterial culture is the most important test for definitive diagnosis. MAC grows within 2–4 weeks in the BACTEC culture system. Anemia (Hb <10 g/dL), thrombocytopenia, and alkaline phosphatase elevated 3–5 times or more are characteristic blood test findings. Bone marrow biopsy shows macrophages containing MAC. Abdominal CT shows hepatosplenomegaly and intra-abdominal lymphadenopathy.

Measuring the CD4 T-cell count: directly linked to the risk of infection, and essential for treatment decisions and application of prophylaxis. Together with HIV RNA viral load, it is used to assess opportunistic infection risk comprehensively.


8. Screening

Regular screening for mycobacterial infection, especially tuberculosis, in all HIV-infected individuals is strongly recommended in international and Korean guidelines.

Tuberculosis screening: following WHO recommendations, a tuberculosis symptom screen (TB symptom screen: positive if any of current cough, fever, night sweats, or weight loss is present) is performed at every visit in all HIV patients. If the symptom screen is positive, chest X-ray and GeneXpert MTB/RIF are performed immediately. For latent tuberculosis infection (LTBI) screening, IGRA (QuantiFERON-TB Gold Plus, etc.) is performed at the first visit and after high-risk tuberculosis exposure. At CD4 <200/μL, false-negative IGRA is likely, so clinical judgment is important.

MAC screening: in patients with CD4 <50/μL, active MAC infection is checked by symptom assessment (fever, weight loss, diarrhea, abdominal pain, etc.) before starting MAC prophylaxis. If symptoms are present, blood mycobacterial culture is performed to exclude active infection before starting prophylaxis. When the CD4 count recovers to 100/μL or above after ART initiation, MAC prophylaxis can be stopped.

An enhanced tuberculosis screening protocol is applied to HIV patients from, or with a history of residence in, tuberculosis-endemic countries (Africa, Southeast Asia, Central Asia).


9. Diagnosis

Diagnosis of tuberculosis: GeneXpert MTB/RIF (Cepheid Xpert MTB/RIF Ultra) is currently the first-line diagnostic test for HIV-associated tuberculosis recommended by the WHO, and can simultaneously detect M. tuberculosis DNA and rifampin resistance in various specimens such as sputum, lymph node aspirate, cerebrospinal fluid, and gastric aspirate (results within 2 hours). Sensitivity is about 88–95% in sputum, and specificity is >98% in patients with no prior antituberculosis treatment. Traditional sputum AFB smear has low sensitivity in HIV patients (~50%) and should not be relied on alone. Culture (Löwenstein-Jensen or MGIT liquid medium) confirms the diagnosis, and drug susceptibility testing is performed. In the diagnosis of CSF tuberculosis, GeneXpert has a sensitivity of about 62–80%, superior to earlier tests, but its positive predictive value may be low, so clinical judgment is needed. Serum ADA (adenosine deaminase) is used adjunctively for diagnosing tuberculous pleural effusion and ascites.

Diagnosis of MAC: blood mycobacterial culture is the gold standard for diagnosing disseminated MAC and is cultured in BACTEC Myco/F Lytic medium. For MAC confirmation, identification tests (high-performance liquid chromatography, nucleic acid probes, or MALDI-TOF) are performed. Culture and histology of bone marrow, lymph node, and liver biopsy tissue (observation of acid-fast bacilli within macrophages) are also useful for diagnosis.


10. Treatment

Treatment of HIV-TB: the standard antituberculosis regimen is a 6-month regimen consisting of an intensive phase of 2 months (isoniazid + rifampin + pyrazinamide + ethambutol, HRZE) and a continuation phase of 4 months (HR). In HIV patients, ART should be started as soon as possible (within 2–8 weeks) after starting tuberculosis treatment. If CD4 <50/μL, the guideline recommendation is to start ART within 2 weeks after starting tuberculosis treatment. Management of drug interactions between ART and antituberculosis drugs is important: rifampin is a major CYP3A4 inducer that greatly lowers blood concentrations of most protease inhibitors (PIs), so efavirenz (EFV)-based ART is preferred during rifampin-based tuberculosis treatment. Considering drug interactions, dolutegravir (DTG)-based ART can also be used (DTG dose adjustment needed). For MDR-TB, new treatment options such as the BPaL regimen based on bedaquiline + pretomanid + linezolid are used.

Treatment of HIV-MAC: clarithromycin 500 mg twice daily + ethambutol 15 mg/kg/day is the basic regimen, and rifabutin is added in severe infection. Azithromycin can be used instead of clarithromycin. As for treatment duration, if the CD4 count is sustained at 100/μL or above after ART initiation, discontinuation can be considered after a minimum of 12 months of treatment. Treatment of latent tuberculosis (LTBI): INH for 9 months (INH 300 mg/day), INH + rifampin for 3 months (3HR), or rifampin for 4 months (4R), etc., are recommended.

IRIS management: TB-IRIS is common 2–8 weeks after ART initiation and presents as fever, lymph node enlargement, worsening pulmonary infiltrates, etc. Most cases are self-limited, but in severe IRIS (e.g., cerebral edema in CNS tuberculosis IRIS), prednisolone is recommended.


11. Prognosis

The prognosis of HIV-associated mycobacterial infection has improved greatly with the combination of ART and appropriate antimycobacterial treatment.

Prognosis of HIV-TB: when ART and tuberculosis treatment are given together, the treatment success rate (treatment completion or cure) is about 80% or more, and mortality is reduced by about 65% compared with treating tuberculosis alone without ART. However, mortality is high when diagnosis is delayed, when MDR-TB/XDR-TB is present, or when the CD4 count is extremely low (≤50/μL). Tuberculous meningitis has a mortality of 30–50% in HIV patients.

Prognosis of HIV-MAC: in the pre-ART era, median survival in disseminated MAC infection was only about 4–6 months. With the combination of ART and anti-MAC treatment, symptoms improve markedly and survival is prolonged. Once the CD4 count recovers sufficiently after ART, MAC maintenance therapy can be stopped.

Prognosis of HIV patients in Korea: the life expectancy of HIV patients in Korea who start ART early and maintain high treatment adherence has improved to nearly the same level as the general population. In patients without tuberculosis or MAC infection who maintain ART well, the CD4 count and HIV RNA suppression are the most important indicators of prognosis.


12. Prevention

Tuberculosis prevention: treatment of latent tuberculosis infection (LTBI) is the most effective tuberculosis prevention strategy. A 9-month INH preventive regimen is given to patients who are IGRA-positive or have had high-risk tuberculosis exposure. Because ART itself greatly reduces the risk of tuberculosis reactivation through CD4 recovery, early ART initiation in all HIV patients is key to tuberculosis prevention. BCG vaccination is effective for preventing severe tuberculosis (miliary, meningitis) in infants, but its effect in preventing pulmonary tuberculosis in adults is limited and it is not recommended in HIV-infected adults owing to concerns about live vaccine adverse effects.

MAC prevention: in patients with CD4 <50/μL, azithromycin (1,200 mg once weekly) or clarithromycin (500 mg twice daily) is given for MAC prophylaxis. If the CD4 count is maintained at 100/μL or above for 3 months or more after ART initiation, prophylaxis can be stopped. Reducing environmental exposure (minimizing contact with unwashed soil and raw birds) is theoretically recommended, but the actual preventive effect depends mainly on drug prophylaxis.

General principle of prevention of HIV opportunistic infections: early initiation of ART and sustained adherence keep the CD4 count high and are fundamental to preventing all opportunistic infections.


13. References

  1. WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. Available at: www.who.int.

  2. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471-1481. DOI: 10.1056/NEJMoa1013911. PMID: 22010913.

  3. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999;340(5):367-373. DOI: 10.1056/NEJM199902043400507. PMID: 9929528.

  4. Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis. 1992;165(6):1082-1085. DOI: 10.1093/infdis/165.6.1082. PMID: 1588145.

  5. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. AIDSinfo. Updated 2023. Available at: clinicalinfo.hiv.gov.

  6. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa. AIDS. 2006;20(12):1605-1612. DOI: 10.1097/01.aids.0000238408.93690.76. PMID: 16868449.

  7. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 1996;335(6):392-398. DOI: 10.1056/NEJM199608083350602. PMID: 8678930.

  8. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516-523. DOI: 10.1016/S1473-3099(08)70184-1. PMID: 18652998.

  9. Kim HN, Scott JD, Spach DH. Management of tuberculosis in people living with HIV. Top Antivir Med. 2021;29(1):16-24. PMID: 33690148.

  10. Korean Society for AIDS; Korean Society of Infectious Diseases. Korean Guidelines for Diagnosis and Treatment of HIV/AIDS. Infect Chemother. 2021;53(4):e54. DOI: 10.3947/ic.2021.0091. PMID: 34910839.